Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jeremy Prine

Interventional Pain Medicine Macon, GA Medical Doctor

NPI 1508000332 CMS profile 1299325

3200 Riverside Dr, Bldg C, Macon, GA 31210

Open in the dashboard

General payments

$6,720

103 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jeremy Prine of Macon, GA is reported in the CMS Open Payments database as having received $6,720 across 103 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 64th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,152 19
2024 General $954 20
2023 General $925 15
2022 General $605 15
2021 General $1,334 25
2020 General $455 6
2019 General $295 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeremy Prine
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Jeremy Prine were reported at $2,152. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Jeremy Prine Interventional Pain Medicine median Middle half National median
2019 $295 $684 $216–$2,079 $163
2020 $455 $382 $122–$1,109 $114
2021 $1,334 $552 $167–$1,554 $132
2022 $605 $605 $187–$1,924 $149
2023 $925 $671 $195–$1,915 $160
2024 $954 $684 $206–$1,837 $164
2025 $2,152 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $2,961 43 payments
  2. Abbott Laboratories $1,388 32 payments
  3. Nevro Corp. $1,213 18 payments
  4. Foundation Fusion Solutions, LLC $437 1 payment
  5. SPR Therapeutics, Inc $174 3 payments
  6. SI-BONE, Inc. $148 1 payment
  7. Stryker Corporation $145 1 payment
  8. Biodelivery Sciences International, Inc. $125 1 payment
  9. Medline Industries, Inc. $88 1 payment
  10. Vertex Pharmaceuticals Incorporated $24 1 payment
  11. Other $18 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,720 103 payments
Products named General payments · program years 2019–2025
  1. General - Pain Management $1,370 13 payments
  2. Proclaim IPG $616 14 payments
  3. Omnia $558 9 payments
  4. Senza $373 5 payments
  5. PROCLAIM $359 12 payments
  6. Proclaim Family of SCS IPGs $299 4 payments
  7. WaveWriter Alpha Prime 16 $187 6 payments
  8. Senza Spinal Cord Stimulation System $178 3 payments
  9. SPRINT PNS System $174 3 payments
  10. IFUSE IMPLANT $148 1 payment
  11. Other $725 16 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 30 drugs

Part D claims

5,529

Median for Pain Management: 951

Drug cost

$138,141

Median for Pain Management: $26,034

Branded share of claims

48.2%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 1,924 $48,342
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 531 $14,933
Movantik Naloxegol Oxalate Brand 35 $14,003
Pregabalin Generic 475 $12,276
Lidocaine Generic 85 $8,885
Gabapentin Generic 472 $6,642
Diclofenac Sodium Generic 107 $5,583
Lidocaine-Prilocaine Lidocaine/Prilocaine Brand 69 $3,421
Tizanidine Hcl Generic 317 $3,397
Buprenorphine Generic 13 $3,154

The 10 drugs with the highest cost, of 30 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 48 billing codes

Paid by Medicare

$457,107

Of which drugs: $295

Medicare patients

556

Average age 74

Services billed

7,058

343 women, 213 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Chronic kidney disease 43%
Diabetes 39%
Ischemic heart disease 33%
Depression 29%
Osteoporosis 23%
COPD 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 68 767 $64

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
PROLATE
  • Forte Bio-Pharma LLC $14
$14 — —
NALOCET
  • Forte Bio-Pharma LLC $4
$4 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

103 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record